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Introduction: SCA38 (MIM 611805) caused by mutations within the ELOVL5 gene, which encodes an
enzyme involved in the synthesis of long-chain fatty acids with a high and specific expression in Purkinje
cells, has recently been identified.
Objective: The present study was aimed at describing the clinical and neuroimaging features, and the
natural history of SCA38.
Methods: We extended our clinical and brain neuroimaging data on SCA38 including 21 cases from three
Italian families. All had the ELOVL5 c.689G > T (p.Gly230Val) missense mutation.
Results: Age at disease onset was in the fourth decade of life. The presenting features were nystagmus
(100% of cases) and slowly progressive gait ataxia (95%). Frequent signs and symptoms included pes cavus
(82%) and hyposmia (76%); rarer symptoms were hearing loss (33%) and anxiety disorder (33%). The
disease progressed with cerebellar symptoms such as limb ataxia, dysarthria, dysphagia, and ophtal-
moparesis followed in the later stages by ophtalmoplegia. Peripheral nervous system involvement was
present in the last phase of disease with sensory loss. Dementia or extrapyramidal signs were not
detected. Significant loss of abilities of daily living was reported only after 20 years of the disease. Brain
imaging documented cerebellar atrophy with sparing of cerebral cortex and no white matter disease.
Conclusions: SCA38 is a rare form of inherited ataxia with characteristic clinical features, including pes
cavus and hyposmia, that may guide genetic screening and prompt diagnosis in light of possible future
therapeutic interventions.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Autosomal dominant spinocerebellar ataxias (SCAs) are a highly
heterogeneous group of movement disorders characterized by gait
ataxia, eye movement deficits, dysarthria, and limb ataxia, usually
associated with cerebellar atrophy [1]. To date, thirty-seven lociand Experimental Sciences,
5100, Italy.
Ltd. This is an open access article uhave been associated with SCA phenotypes with 29 defective genes
identified (neuromuscular.wustl.edu/ataxia/domatax/html). How-
ever, many SCA families are still gene-orphans [1]. The majority of
SCAs are caused by an expansion or insertion of a trinucleotide or
polynucleotide repeat, including SCA1e3, SCA6e8, SCA10, SCA12,
SCA17, SCA31, SCA36 and DRPLA. The remaining forms are caused
by conventional mutations or re-arrangements in the correspond-
ing genes [2].
Gait disorders are the initial symptom in two-thirds of all pa-
tients with SCA [3], and the clinical picture becomes more complexnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Phenotypic differences seem to allow a distinction between
autosomal dominant cerebellar ataxias caused by polyglutamine
expansions and conventional mutations. Genetic anticipation is
present in polyglutamine expansion SCAs, which generally have a
disease onset in the third or fourth decade of life, inversely corre-
lated to the number of CAG repeats in the corresponding gene [2,6].
Polyglutamine SCAs are multisystem diseases with rapid progres-
sion, while conventional mutations are generally associated with a
pure form of ataxia and slow disease progression [1].
Polyglutamine expansions are more frequently associated with
more severe forms of SCA and thus more extensive atrophy
affecting the brainstem [7].
Since the phenotypes may be very heterogeneous and some-
times confusing between the different SCAs, characteristic signs are
warranted for a rapid clinical diagnosis.
We recently identified SCA38 (MIM 611805) caused by muta-
tions within the ELOVL5 gene [8], which encodes an enzyme
involved in the synthesis of long-chain fatty acids with a high and
specific expression in Purkinje cells [9].
In the present study, we extended the analysis of the SCA38
phenotype expanding the patients' cohort and reporting the clin-
ical features, course of the disease and neuroimaging hallmarks of
the disease.2. Methods
2.1. Subjects
We collected clinical and neuroradiological information from
twenty-one SCA38 cases carrying the c.689G > T (p.Gly230Val)
mutation in ELOVL5. All patients belonged to the three Italian
pedigrees described in the paper which originally reported the
gene identification [8], where we also summarized the phenotype
of three cases, further characterized herein (SCA38-01-BS, SCA38-
02-CA and SCA38-03-TO, Fig. 1). An experienced clinician recorded
clinical data of all studied cases.
Patients had been evaluated over the course of the disease, and
signs and symptoms were periodically recorded each year. Avail-
able clinical evaluations were divided into three groups according
to the onset of the disease: first decade (0e10 years from the onsetFig. 1. Pedigrees of the three Italian families with SCA38. Unfilled symbols indicate unaffecte
indicates individuals for whom DNAwas available. The genotype of the ELOVL5mutations is i
by a “±” below the symbol.of symptoms), second decade (11e20 years from the onset of
symptoms), and third decade and over (over 20 years from the
onset of symptoms). For each decade, wemeasured the incidence of
symptoms by using a person-years approach. Cumulative incidence
was expressed as the number of cases with the considered symp-
tom out of the total number of person-years individuals at risk [10].
Clinical assessment was further accomplished by structural and
functional imaging studies, and electrophysiological examinations,
according to standard procedures. Patients underwent brain MRI
(1.5 T), and atrophy was examined by visual evaluation of T1 se-
quences by expert neurologists and scored as absent () or present
(þ: mild, þþ: moderate, þþþ: severe). Electromyography/elec-
troneurography examinations considered the presence of periph-
eral neuropathy, according to standard procedures in the different
participating centres.2.2. Mutation screening of ELOVL5
We screened the c.689G > T (p.Gly230Val) mutation in exon 7 of
ELOVL5 by Sanger sequencing. PCR conditions were: 10 mMol
primers (50-gtatgtgttgtgttcatgaagtgactg; 50-gctcca-
catgcccattaagtaaata), 200 mMol dNTPs, 60 ng of genomic DNA, and
0.5 units of KAPA-fast 2G kit (Kapa Biosystems, Inc., MA, USA) with
a 25 ml final volume under standard amplification conditions (56 C
annealing temperature). PCR products were purified using Agen-
court AMPure XP-PCR Purification (Beckman Coulter, Miami, FL,
USA) and sequenced with the Big Dye v3.1 kit (Applied Biosystems,
Foster City, CA, USA). Products were purified using Agencourt
CleanSEQ-Dye Terminator Removal (Beckman Coulter) and run on a
ABI-3730 platform, using POP7 polymer (Applied Biosystems).
Electropherograms were analysed with the SeqScape software
version 2.6 (Applied Biosystems), as previously described [8].2.3. Standard protocol approvals
The study conformed to the Declaration of Helsinki principles.
The study protocol was approved by the Ethics Committee of
Brescia Hospital, Brescia, Italy.
All participants signed a written informed consent form.d family members, and solid black symbols affected members. A line above the symbol
ndicated below each tested subject. Individuals carrying ELOVL5mutation are indicated
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3.1. Clinical features and disease course
We collected clinical data from 21 patients with the c.689G > T
(p.Gly230Val) mutation in the ELOVL5 gene from three Italian
families. The disease showed a pattern of fully penetrant autosomal
dominant disease by 50 years of age.
All affected members showed a relatively homogeneous
phenotype with reference to neurological symptoms and disease
progression. As reported in Table 1, the mean age at onset was 39.1
years (range 26e50 years) with no evidence of genetic anticipation,
and no significant gender bias (10 females, 11 males).
The first sign of the disease was unbalanced gait, and in some
cases slurred speech. At neurological examination, patients pre-
sented nystagmus, in the lateral and vertical gaze (100%), and gait
ataxia (95%). In one case, dysarthria was the first presenting
symptom (5%), and in a second dysarthria was the first presenting
symptom along with gait ataxia (5%).
At the first neurological examination, further features were
observed in the majority of patients such as pes cavus (14/17, 82.3%)
and hyposmia (13/17, 76.5%). Less frequently we observed hearing
loss (7/21, 33.3%) and anxiety disorder (7/21, 33.3%), the two latter
symptoms were present only in patients from SCA38-02-CA fam-
ilies. No other comorbidities were significantly associated with the
disease, including epilepsy and significant metabolic diseases.
Forty-three cumulative clinical evaluations were available: 22 in
the first decade from onset, 13 in the second decade, and 8 in the
third decade (Fig. 2, panel A). Gait ataxia and nystagmus were the
most frequent features in the early disease stage, whereas limb
ataxia, and dysarthriawere present in almost half of the cases in the
first decade, and increased in frequency in the more advanced
stages. Dysphagiawas a rare symptom in the first two decades from
onset. Half of the patients developed dysphagia in the third decade.
At the beginning of the disease ocular anomalies included
diplopia on the horizontal line and were present in half of the cases
in the second decade. As the disease progressed, patients devel-
oped ophtalmoparesis, which became ophtalmoplegia in almost
40% of cases, after 20 years of the disease.Table 1
Clinical features of SCA38 cases.
Patient Pedigree Gender Age at last evaluation Age at onset Sym
III-6 SCA38-01-BS F 59 45 gait
III-10 SCA38-01-BS F 60 38 gait
III-1 SCA38-01-BS F 76 40 gait
III-2 SCA38-01-BS F 74 33 gait
II-6 SCA38-01-BS M 80 (deceased) 50 gait
II-3 SCA38-01-BS M 91 (deceased) 45 gait
IV-2 SCA38-01-BS M 43 38 gait
IV-1 SCA38-01-BS F 45 38 gait
IV-8 SCA38-02-CA F 48 35 gait
III-5 SCA38-02-CA M 80 38 gait
IV-11 SCA38-02-CA F 43 38 gait
IV-9 SCA38-02-CA M 47 37 gait
IV-12 SCA38-02-CA M 38 34 gait
IV-10 SCA38-02-CA M 46 46 gait
III-14 SCA38-02-CA F 55 37 gait
III-13 SCA38-02-CA M 66 30 gait
IV-27 SCA38-02-CA M 32 30 gait
IV-26 SCA38-02-CA F 33 26 gait
III-4 SCA38-03-TO M 70 (deceased) 50 gait
III-3 SCA38-03-TO F 72 50 gait
IV-6 SCA38-03-TO M 47 44 dysa
47% F (10/21) - mean 39.1 -
F: female; M: male; dys.: dysarthria; n.a.: not available; þ: presence of sign/symptom; -Sensory loss increased in frequency over time, being present in
40e50% of patients after 10 years from onset. Babinski reflex was
rarely reported, and only in the later stages of the disease.
Neither cognitive impairment, nor bradykinesia, tremors, hy-
pertonia, myoclonus nor dystonia was associated with SCA38.
Overall, SCA38 was a slowly progressive disorder (Fig. 2, panel
B). In the first decade of the disease, all patients were independent
in basic activities of daily living. In the second decade, 70% of pa-
tients had walking difficulties and a cane was needed, and almost
30% had dressing andwashing difficulties. In the third decade of the
disease, almost 80% of patients were wheelchair-bound and not
independent in basic activities of daily living; half of them had to be
helped with feeding, whereas incontinence was a very rare finding.
The mean disease duration from onset to death (available in 3
patients) was 41 years (range 20e52). The cause of death was
hearth disease (2 cases) and pulmonary infection (1 case) at the age
of 70, 80 and 91 years old, respectively.3.2. Neuroimaging features
Brain MRI showed mild cerebellar atrophy mainly affecting the
vermis, with normal brainstem and no cerebral cortex atrophy.
These findings were supported by functional brain FDG-Positron
Emission Tomography (FDG-PET) studies, which confirmed selec-
tive hypometabolism of the cerebellar vermis and of the cerebellar
hemisphere to a lesser extent (in Fig. 3, structural and functional
brain studies in two SCA38 patients, namely cases III:10 and III:6,
family SCA38-01-BS).
As reported in Supplementary Table, visual rating of the avail-
able MRI scans over the course of the disease (14 patients evaluated
over time with 25 MRI scans available) confirmed selective cere-
bellar atrophy with spared brainstem and cerebral cortex in almost
all cases. No significant white matter disease was observed. Only
one patient had significant cortical atrophy and white matter ab-
normalities, but along with significant cerebrovascular comorbid-
ities and previous strokes (III:4, family SCA38-03-TO).ptom at onset Additional clinical features
Pes cavus Hearing loss Hyposmia Anxiety disorder
ataxia e - þ -
ataxia þ - þ -
ataxia þ - þ -
ataxia n.a. þ n.a. -
ataxia n.a. - n.a. -
ataxia n.a. - n.a. -
ataxia - - - -
ataxia - - - -
ataxia þ þ þ þ
ataxia þ þ þ þ
ataxia þ þ þ þ
ataxia þ þ þ þ
ataxia þ þ þ þ
ataxia þ þ - -
ataxia þ - þ þ
ataxia þ - n.a. þ
ataxia n.a. - þ -
ataxia þ - þ -
ataxia, dys. þ - þ -
ataxia þ - - -
rthria þ - þ -
82.3% (14/17) 33.3% (7/21) 76.5% (13/17) 33.3% (7/21)
: absence of sign/symptom.
Fig. 2. Signs and symptoms (panel A) and loss of activities of daily living (panel B) of SCA38 patients according to decades from disease onset. In grey, symptoms reported in the first
10 years of the disease, in blue those reported from 10 to 20 years of the disease, in violet those reported over 20 years from the onset of symptoms. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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To further characterize SCA38, peripheral nerve electrophysio-
logical studies and evoked potentials were performed. The con-
duction velocities study and electromyography (EMG) denoted
sensory-motor axonal polyneuropathy at four limbs, and was
pathological in all 9 available cases but one, who performed EMG
one year from disease onset.
Auditory evoked potentials, markers of brainstem damage, were
available in 12 of the 20 patients, and they were found to be
pathological in 92% of cases (11/12). Somatosensory and motor
evoked potentials led to variable findings, showing alterations in
33% (3/9 and 1/3) of patients, respectively, and in later disease
stages. Visual evoked potentials were found to be unremarkable
overall in all 8 cases available.4. Discussion
In this study, we provide clinical and neuroradiological detailson SCA38, a recently described form of autosomal dominant ataxia
[8]. The availability of cases for phenotype characterization is
presently limited to three Italian families, which were however
enough to allow us to gather 21 cases. All have the same ELOVL5
c.689G > T (p.Gly230Val) mutation: two of the families were
related to one another, whereas for the third a common ancestor
was not demonstrated [8].
Cases with different mutations may in future reveal a broader
phenotypic spectrum, but on the other hand the study of many
patients with the same mutation is a unique opportunity to define
the disease characteristics associated with the shared variant.
Conventional mutations in spinocerebellar ataxia genes are
suggested to lead to a milder phenotype and a slower progressive
disorder if compared to polyglutamine expansions [1]. SCA38
seems to confirm this rule, with an onset in the fourth-fifth decade
of life, and complete penetrance by age 50 is a common finding,
shared by many forms of SCAs [2].
The neurological picture is that of a pure cerebellar ataxia with
symptoms including gait ataxia, nystagmus and dysarthria as the
Fig. 3. Structural and functional neuroimaging findings in two patients with SCA38 (SCA38-01-BS III:10 and SCA38-01-BS III:6). Panel A. Coronal, sagittal and axial magnetic
resonance imaging sections (MRI). Panel B. FDG-PET images were processed by Statistical Parametric Mapping (SPM8), and single-subject analysis using a group of 19 healthy
controls (mean age: 53 years; female: 59%) was performed (patient < controls) and results were superimposed to T1 MRI template. Statistical threshold was set at P < 0.001,
uncorrected for multiple comparisons, with voxel threshold ¼ 100 voxels.
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SCA38 and may help the diagnosis: pes cavus without paraparesis
(82%) and early hyposmia/anosmia (73%). Pes cavus has never been
described in SCAs, while olfactory deficit has recently been re-
ported in SCA3 [11,12], SCA7 [13] and in SCA2 [14].
Other features may help in the differential diagnosis of SCA: 1)
eye movement anomalies, frequently associated with polyglut-
amine expansion SCAs [15,16], and with SCA28 in which ophtal-
moplegia and ptosis have been described at later stages [18]; 2)
peripheral sensory loss, although quite a common symptom in
hereditary ataxias [19,20]; 3) the absence of cognitive decline and
extrapyramidal movement disorders suggests the lack of involve-
ment of cortical and subcortical brain regions, and excludes a
subset of autosomal dominant ataxias (e.g., SCA8, 13, 17, 21 and
DRPLA).
Hearing loss detected at diagnosis, and supported by auditory
evoked potential deficit, was not very common (33.3%), previously
reported only in SCA36 [21], and debated in SCA31 [22]. Anxiety
disorder might be considered an additional symptom for SCA38,
present in 33.3%, of the reported cases; however, this was present
in only one family, and further cases may elucidate the specific
association between SCA38 and anxiety disorder.
The disease is slowly progressive with significant functional
impairment occurring only after the third decade from the onset of
the disease.
Brain MRI showed selective cerebellar atrophy without signifi-
cant involvement of the cerebral hemispheres. No significant white
matter disease was associated with SCA38.
SCA38 and SCA34 are two spinocerebellar ataxias associated
with the synthesis of Poly Unsaturated Fatty Acids (PUFAs) with
more than 20 carbon atoms [23]. Pathogenic mechanisms are still
to be elucidated in both these diseases, although our previous work
detected decreased level of ELOVL5 products in patients' serum,
indicating that Gly230Val mutation might affect the elongase ac-
tivity of this enzyme causing a loss of function mechanism. In these
new series of patients, we could not collect further serum samples
for measuring PUFA levels.
On the other hand, we had initial evidence that the mutantELOVL5 protein is not degraded, but upregulated and delocalized
suggesting that it gains a toxic function. Both loss and gain of
function might therefore be effective in causing SCA38.
Interestingly, ELOVL4, another elongase involved in the synthe-
sis of fatty acids, has recently been described in a single Canadian
family with an autosomal dominant form of cerebellar ataxia with
or without erythrokeratodermia (SCA34, OMIM133190) [24]. The
clinical features of SCA34 resembled to some extent those of SCA38,
being slowly progressive with onset in the fourth/fifth decade of
life, with no cognitive impairment and axonal peripheral neurop-
athy [25,26].
Mutations in ELOVL4 have been associated with autosomal
dominant Startgard macular dystrophy disease type 3 (MIM
600110) and an autosomal recessive form of spastic quadriplegia
with ichthyosis and mental retardation (MIM 614457). The het-
erogeneous clinical picture associated with ELOVL4 mutations is
intriguing and mirrors the role of ELOVL4 products in the skin, eye
and brain. We may speculate that mutations affecting specific
ELOVL5 domains, or both alleles, might also therefore be associated
with clinical features that are phenotypically different from SCA38.5. Conclusion
In conclusion, we extended the survey and detailed the
phenotypic spectrum associated with the Gly230Val mutation in
ELOVL5. Our study suggests that the presence of pes cavus without
paraparesis and early hyposmia/anosmia, in cases with a pure form
of cerebellar ataxia would be hallmarks for testing SCA38 as the
first tier genetic analysis. Ophtalmopharesis and ophthalmoplegia
may be considered in advanced cases.
Further assessment of disease heterogeneity and further char-
acterization of the clinical picture of SCA38 by evaluation of other
causative mutations will be warranted.
The identification of further cases may be also instrumental in
clarifying the pathogenic mechanism of SCA38 in light of future
therapeutic approaches.
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